Evidence map›Paper›PMID 38392260›Full record

ArticleJournal of cardiovascular development and disease2024

One Year Outcomes Following Transplantation with COVID-19-Positive Donor Hearts: A National Database Cohort Study.

Stanley B Wolfe, Ruby Singh, Dane C Paneitz, Seyed Alireza Rabi, Chijioke C Chukwudi, Richa Asija, Eriberto Michel, Asvin M Ganapathi, Asishana A Osho

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cardiovascular development and disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Stanley B WolfeDivision of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Ruby SinghDivision of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0003-2664-2338
Dane C PaneitzDivision of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Seyed Alireza RabiDivision of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Chijioke C ChukwudiDivision of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-4711-1264
Richa AsijaDivision of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Eriberto MichelDivision of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Asvin M GanapathiDivision of Cardiac Surgery, Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Asishana A OshoDivision of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Harvard University · USThe Ohio State University Wexner Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current understanding of the safety of heart transplantation from COVID-19+ donors is uncertain. Preliminary studies suggest that heart transplants from these donors may be feasible. We analyzed 1-year outcomes in COVID-19+ donor heart recipients using 1:3 propensity matching. The OPTN database was queried for adult heart transplant recipients between 1 January 2020 and 30 September 2022. COVID-19+ donors were defined as those who tested positive on NATs or antigen tests within 21 days prior to procurement. Multiorgan transplants, retransplants, donors without COVID-19 testing, and recipients allocated under the old heart allocation system were excluded. A total of 7211 heart transplant recipients met the inclusion criteria, including 316 COVID-19+ donor heart recipients. Further, 290 COVID-19+ donor heart recipients were matched to 870 COVID-19- donor heart recipients. Survival was similar between the groups at 30 days (

Indexed as

coronavirus disease 2019COVID-19 donor heartsdonor selectionheart transplantrecipient survivaltransplant outcomes

Identifiers

PMID38392260
PMCPMC10889800
OpenAlexW4391384134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.